[Clinical studies on cefixime in pediatrics].

Area of Science:

• Pediatric Infectious Diseases
• Clinical Pharmacology
• Bacteriology

Background:

• Bacterial infections are a common cause of illness in children.
• Effective and safe oral antibiotics are crucial for pediatric care.
• Cephalosporins represent a key class of antibiotics used in treating bacterial infections.

Purpose of the Study:

• To evaluate the therapeutic effectiveness and safety of cefixime (CFIX), a novel oral cephalosporin, in pediatric patients.
• To assess the clinical and bacteriological response to CFIX in children with various bacterial infections.

Main Methods:

• A clinical study involving 13 pediatric patients with bacterial infections.
• Oral administration of cefixime (CFIX) at dosages ranging from 5.1 to 17.4 mg/kg/day.
• Treatment duration varied from 3 to 10 days, with an average of 5.8 days.

Main Results:

• Overall clinical efficacy rate of 84.6% (4 excellent, 7 good responses).
• Bacteriological efficacy was good, with 6 of 8 identified causative organisms eradicated.
• Side effects were mild and infrequent, including loose stool and transient liver enzyme elevations in 3 patients.

Conclusions:

• Cefixime (CFIX) is a useful and effective oral cephalosporin for treating bacterial infections in children.
• The drug demonstrated a favorable clinical and bacteriological response profile.
• CFIX presents a promising therapeutic option for pediatric bacterial infections with a good safety profile.